Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
281.3 AUD | +0.44% | +0.25% | -1.85% |
May. 30 | US nears deal to fund Moderna's bird flu vaccine trial, FT reports | RE |
May. 27 | US, European nations consider vaccinating workers exposed to bird flu | RE |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 49.55 and 41.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.85% | 89.87B | A- | ||
-3.95% | 37.57B | A- | ||
+60.96% | 26.47B | A | ||
-22.14% | 14.25B | C | ||
-7.96% | 12.99B | B- | ||
-9.33% | 11.93B | D+ | ||
-46.33% | 10.84B | B | ||
+4.19% | 9.11B | B+ | ||
-19.42% | 7.32B | B- | ||
+88.73% | 7.14B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CSL Stock
- Ratings CSL Limited